

**LISTING OF THE CLAIMS AS AMENDED**

1. (currently amended) A method for inducing T-cell tolerance non-responsiveness to an allogeneic or xenogeneic donor tissue or organ in a human recipient of the tissue or organ comprising administering to the recipient prior to transplantation of the tissue or organ:
  - (a) an allogeneic or xenogeneic a donor cell which expresses at least one donor antigen and which mediates contact-dependent helper effector function; and
  - (b) an anti-human gp39 antibody, whereby contact dependent helper effector function is inhibited.
2. (canceled)
3. (canceled)
4. (currently amended) The method of claim 1, wherein the anti-human gp39 antibody is a monoclonal antibody.
5. (canceled)
6. (canceled)
7. (original) The method of claim 4, wherein the monoclonal antibody is a chimeric monoclonal antibody.
8. (original) The method of claim 4, wherein the monoclonal antibody is a humanized monoclonal antibody.
9. (original) The method of claim 1, wherein the allogeneic or xenogeneic cell is a lymphoid cell.
10. (original) The method of claim 9, wherein the lymphoid cell is a B cell.

11. (original) The method of claim 10, wherein the B cell is a resting B cell.

12. (canceled)

13. (original) The method of claim 1, wherein the tissue or organ comprises pancreatic islets.

14. (original) The method of claim 1, wherein the tissue or organ is selected from the group consisting of liver, kidney, heart, lung, skin, muscle, neuronal tissue, stomach and intestine.

15. (currently amended) A method for inducing T cell ~~tolerance~~ non-responsiveness to an allogeneic or xenogeneic donor tissue or organ in a human recipient of the tissue or organ comprising administering to the recipient prior to the transplantation of the tissue or organ

- (a) ~~an allogeneic or xenogeneic~~ a donor cell which expresses at least one donor antigen; and
- (b) an anti-human gp39 antibody, whereby T cell ~~tolerance~~ non-responsiveness to ~~a~~ the allogeneic or xenogeneic donor tissue or organ, which expressed the donor antigen, in a human recipient of the tissue or organ is induced.

16. (canceled)

17. (original) The method of claim 15, wherein the anti-human gp39 antibody is a monoclonal antibody.

18. (canceled)

19. (canceled)

20. (original) The method of claim 17, wherein the monoclonal antibody is a chimeric monoclonal antibody.

21. (original) The method of claim 17, wherein the monoclonal antibody is a humanized monoclonal antibody.

22. (canceled)

23. (canceled)

24. (original) The method of claim 15, wherein the allogeneic or xenogeneic cell is a lymphoid cell.

25. (original) The method of claim 24, wherein the lymphoid cell is a B cell.

26. (original) The method of claim 25, wherein the B cell is a resting B cell.

27. (canceled)

28. (original) The method of claim 15, wherein the tissue or organ comprises pancreatic islets.

29. (original) The method of claim 15, wherein the tissue or organ is selected from the group consisting of liver, kidney, heart, lung, skin, muscle, neuronal tissue, stomach and intestine.

30. (currently amended) A method for treating diabetes comprising administering to a human subject in need of treatment:

- (a) an allogeneic or xenogeneic cell which expresses at least one donor antigen;
- (b) an anti-human gp39 antibody; and
- (c) donor pancreatic islets cells, whereby T cell tolerance non-responsiveness to the donor pancreatic cells is induced.

31. (original) The method of claim 30, wherein the anti-gp39 antibody is a monoclonal antibody.

32. (canceled)

33. (canceled)

34. (original) The method of claim 31, wherein the monoclonal antibody is a chimeric monoclonal antibody.

35. (original) The method of claim 31, wherein the monoclonal antibody is a humanized monoclonal antibody.

36. (canceled)

37. (canceled)

38. (original) The method of claim 30, wherein the allogeneic or xenogeneic cell is a lymphoid cell.

39. (original) The method of claim 38, wherein the lymphoid cell is a B cell.

40. (original) The method of claim 39, wherein the B cell is a resting B cell.

41. (previously amended) The method of claim 30, wherein the allogeneic or xenogeneic cell and the anti-gp39 antibody are administered to the recipient prior to transplantation of the pancreatic islet cells.

42. (currently amended) A method for inducing T cell tolerance non-responsiveness to an allogeneic donor tissue or organ in a human recipient of the tissue or organ comprising administering to the recipient prior to transplantation of the tissue or organ

(a) a donor allogeneic cell; and

(b) an anti-human gp39 antibody, and whereby T cell ~~tolerance~~ non-responsiveness to a tissue or organ comprising the donor allogeneic cell in a human recipient of the tissue or organ is induced.

43. (original) The method of claim 42, wherein the anti-gp39 antibody is a monoclonal antibody.

44. (canceled)

45. (canceled)

46. (original) The method of claim 44, wherein the monoclonal antibody is a chimeric monoclonal antibody.

47. (original) The method of claim 44, wherein the monoclonal antibody is a humanized monoclonal antibody.

48. (original) The method of claim 42, wherein the donor allogeneic cell is a lymphoid cell.

49. (original) The method of claim 48, wherein the lymphoid cell is a B cell.

50. (original) The method of claim 49, wherein the B cell is a resting B cell.

\* \* \* \* \*